Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$80.09
-2.5%		$74.22
$42.09
▼
$93.42
$15.66B0.953.26 million shs2.13 million shs
Evotec SE stock logo
EVTCY
Evotec
$1.91
-1.0%		$2.59
$14.22
▼
$26.57
$630.72M0.982,407 shs34,168 shs
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
$58.70
$58.82
$27.30
▼
$64.41
$4.12B0.772.76 million shsN/A
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
0.00%-4.68%+3.76%+16.82%+75.56%
Evotec SE stock logo
EVTCY
Evotec
-1.04%-1.55%-32.98%-38.19%-54.95%
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$80.09
-2.5%		$74.22
$42.09
▼
$93.42
$15.66B0.953.26 million shs2.13 million shs
Evotec SE stock logo
EVTCY
Evotec
$1.91
-1.0%		$2.59
$14.22
▼
$26.57
$630.72M0.982,407 shs34,168 shs
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
$58.70
$58.82
$27.30
▼
$64.41
$4.12B0.772.76 million shsN/A
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
0.00%-4.68%+3.76%+16.82%+75.56%
Evotec SE stock logo
EVTCY
Evotec
-1.04%-1.55%-32.98%-38.19%-54.95%
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2.83
Moderate Buy$95.2118.88% Upside
Evotec SE stock logo
EVTCY
Evotec
0.00
N/AN/AN/A
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest BBIO, EVTCY, and MRTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/16/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$82.00 ➝ $93.00
7/13/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$110.00 ➝ $120.00
6/16/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$106.00 ➝ $96.00
6/3/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$104.00
5/28/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$94.00 ➝ $98.00
5/28/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$110.00
5/26/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
5/19/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$82.00
5/15/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
5/11/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$100.00 ➝ $110.00
(Data available from 8/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$502.08M31.18N/AN/A($10.77) per share-7.44
Evotec SE stock logo
EVTCY
Evotec
$572.16M1.10$0.02 per share105.53$2.52 per share0.76
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
$12.44M331.01N/AN/A$17.31 per share3.39
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$724.93M-$3.74N/A1,334.83N/A-124.42%N/A-65.81%8/4/2026 (Estimated)
Evotec SE stock logo
EVTCY
Evotec
$7.14M$0.414.66N/AN/A20.85%16.02%7.81%N/A
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
-$740.87M-$12.22N/AN/AN/A-1,900.65%-82.15%-67.82%N/A

Latest BBIO, EVTCY, and MRTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2026Q2 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.5816N/AN/AN/A$221.15 millionN/A
5/7/2026Q1 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.70-$0.84-$0.14-$0.84$178.07 million$194.52 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
Evotec SE stock logo
EVTCY
Evotec
N/AN/AN/AN/AN/A
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
1.52
1.48
Evotec SE stock logo
EVTCY
Evotec
0.53
2.57
2.50
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
N/A
7.54
7.40

Institutional Ownership

CompanyInstitutional Ownership
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
Evotec SE stock logo
EVTCY
Evotec
N/A
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
14.23%
Evotec SE stock logo
EVTCY
Evotec
N/A
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
3.26%
CompanyEmployeesShares OutstandingFree FloatOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
400195.49 million167.67 millionOptionable
Evotec SE stock logo
EVTCY
Evotec
4,200330.22 millionN/ANot Optionable
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
58770.15 million67.86 millionNo Data

Recent News About These Companies

BMS removes 2 clinical programs from pipeline, one from Mirati and another from Exscientia
October 31, 2025  |  fiercebiotech.comF
Mirati's Flagship Drug Faces Mounting Pressure from Lilly's New Therapy
September 4, 2025  |  aktiencheck.deA
Mirati Therapeutics Stock Price History
May 26, 2025  |  investing.comhttps://www.investing.com/equities/mirati-ther-historical-data
New GTPase KRAS mutant inhibitors disclosed in Mirati patent
December 12, 2024  |  bioworld.comB
Mirati Therapeutics Receives Untitled Letter from OPDP for Overstating Cancer Drug Efficacy
October 15, 2024  |  policymed.comP
Pharma M&A rumour mill grinds out Mirati's name again
August 16, 2024  |  pharmaphorum.comP
Mirati's Charles Baum takes the helm at Terremoto Biosciences
July 25, 2024  |  fiercebiotech.comF
Mirati Therapeutics gets grant for combination therapy for treating kras G12C cancers
April 17, 2024  |  pharmaceutical-technology.comP
Mirati Therapeutics gets grant for combination therapy for treating kras G12C cancers
April 17, 2024  |  pharmaceutical-technology.comP
How this insider trader nailed every single stock trade
April 5, 2024  |  finbold.comF
The workforce reduction at Mirati Therapeutics will take place over the next year and impacts more than 400 employees.
April 3, 2024  |  sandiegouniontribune.comS
Mirati Therapeutics files patent for inhibitors of KRAS g12d
March 26, 2024  |  pharmaceutical-technology.comP
Bristol Myers Squibb cuts hundreds of Mirati staffers months after closing $5.8B buyout
March 26, 2024  |  fiercepharma.comF
Bristol Myers Squibb concludes acquisition of Mirati Therapeutics
January 26, 2024  |  medicaldialogues.inM
Bristol Myers Squibb completes acquisition of Mirati Therapeutics
January 25, 2024  |  pharmabiz.comP
Mirati Therapeutics Receives Marketing Authorization For KRAZATI From European Commission
January 10, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/mirati-therapeutics-receives-marketing-authorization-for-krazati-from-european-commission-1032957219
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
January 10, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/european-commission-approves-krazati-adagrasib-130000810.html?.tsrc=rss
Mirati Therapeutics Inc [MRTX] Stock sold by Insider Christensen Jamie for $0.14 million
January 2, 2024  |  knoxdaily.comK
Evaluating Mirati Therapeutics' CVR Value In The Wake Of The Bristol Myers Acquisition
December 25, 2023  |  seekingalpha.comhttps://seekingalpha.com/article/4659531-evaluating-mirati-therapeutics-cvr-value-in-the-wake-of-the-bristol-myers-acquisition
Bristol Myers to buy schizophrenia drugmaker Karuna Therapeutics for $14 bln
December 22, 2023  |  reuters.comhttps://www.reuters.com/markets/deals/bristol-myers-buy-karuna-therapeutics-14-billion-wsj-2023-12-22/?ref=upstract.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
A semiconductor wafer with the SK hynix logo displayed inside a manufacturing fabrication facility.
SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
By Thomas Hughes | July 7, 2026
Rocket Lab Electron rocket on coastal launch pad with company logo overlay, symbolizing space tech integration strategy.
Rocket Lab’s Stock Drop Comes With a Bullish Twist
By Ryan Hasson | July 10, 2026
Two Very Large Crude Carriers (VLLCs) sailing side by side on open ocean waters, viewed from above.
Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit
By Dan Schmidt | July 19, 2026
A digital illustration of a glowing AI brain connected to circuit pathways against a city skyline backdrop.
2 AI Stocks That Could Benefit as AI Moves Beyond the Data Center
By Thomas Hughes | July 5, 2026
A gloved hand holds a white capsule pill in a pharmaceutical laboratory setting.
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
By Jeffrey Neal Johnson | July 13, 2026
BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$80.09 -2.05 (-2.50%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$80.27 +0.18 (+0.22%)
As of 07/31/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Evotec stock logo

Evotec OTCMKTS:EVTCY

$1.91 -0.02 (-1.04%)
As of 07/31/2026

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Mirati Therapeutics stock logo

Mirati Therapeutics NASDAQ:MRTX

Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas